Advertisement

PentaVision

Ophthalmology Management

Article

Faculty

Ophthalmology Management October 1, 2019

MODERATOR Rajesh Rajpal, MD, Chief Medical officer, Avedro, and Owner, See Clearly Vision, Washington, DC.

MODERATOR
Rajesh Rajpal, MD, Chief Medical officer, Avedro, and Owner, See Clearly Vision, Washington, DC.

Nicole Fram, MD, Cataract, Cornea, and Refractive Surgeon, Advanced Vision Care, Los Angeles, and Clinical Instructor, Stein Eye Institute, UCLA. Financial disclosures: Alcon, Allergan, Bausch & Lomb, Bio-Tissue, CorneaGen, Johnson & Johnson, Ocular Science, Shire (Takeda), and Zeiss.

Nicole Fram, MD, Cataract, Cornea, and Refractive Surgeon, Advanced Vision Care, Los Angeles, and Clinical Instructor, Stein Eye Institute, UCLA. Financial disclosures: Alcon, Allergan, Bausch & Lomb, Bio-Tissue, CorneaGen, Johnson & Johnson, Ocular Science, Shire (Takeda), and Zeiss.

Kathryn Hatch, MD, Cornea and Refractive Surgeon and Director of the Refractive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston. Financial disclosures: Avedro, EyePoint, Eyevance, Johnson & Johnson, Shire (Takeda), and Zeiss.

Kathryn Hatch, MD, Cornea and Refractive Surgeon and Director of the Refractive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston. Financial disclosures: Avedro, EyePoint, Eyevance, Johnson & Johnson, Shire (Takeda), and Zeiss.

Jay K. Mattheis, MD, Ophthalmologist, Wellish Vision Institute Laser and Surgery Center, Las Vegas. Financial disclosures: Aerie Pharmaceuticals, Bausch & Lomb, Bio-Tissue, and Shire (Takeda).

Jay K. Mattheis, MD, Ophthalmologist, Wellish Vision Institute Laser and Surgery Center, Las Vegas. Financial disclosures: Aerie Pharmaceuticals, Bausch & Lomb, Bio-Tissue, and Shire (Takeda).

Max Parikh, MD, Medical Director and a Refractive/Anterior Segment Surgeon, NVision Eye Center, La Jolla, CA; Team Ophthalmologist, San Diego Chargers; and Chief Ophthalmologist, Native Americans Rincon-Pauma Valley at Indian Health Clinic. Financial disclosures: Optovue, OASIS Medical, and MacuHealth.

Max Parikh, MD, Medical Director and a Refractive/Anterior Segment Surgeon, NVision Eye Center, La Jolla, CA; Team Ophthalmologist, San Diego Chargers; and Chief Ophthalmologist, Native Americans Rincon-Pauma Valley at Indian Health Clinic. Financial disclosures: Optovue, OASIS Medical, and MacuHealth.

Highlights from a panel discussion held during the 2019 ASCRS Annual Meeting

Optovue, Avedro, and Bio-Tissue, three pioneering ophthalmic companies, welcomed surgeons to a thought-provoking symposium on new technologies in the diagnosis and treatment of anterior segment diseases, held during the American Society of Cataract and Refractive Surgery 2019 meeting in San Diego. The cosponsored symposium features five ophthalmic thought leaders who discussed how breakthrough technologies have influenced diagnosis and treatment for patients seeking cataract or refractive surgery, as well as care for corneal disease. For each company, there is a standout area of expertise: Optovue with the first FDA-approved OCT for Epithelial Thickness Mapping, Avedro with the first and only FDA-approved therapeutic treatment for progressive keratoconus, and Bio-Tissue with cryopreserved amniotic membrane.

Sponsored by





What to Read Next